ABT - Fluidigm Is An Under The Radar Beneficiary From The Shortage Of COVID-19 Diagnostics Equipment
This article was highlighted for PRO subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here.
Executive Summary and Investment Conclusion
After multiple years of negative earnings revisions and a stagnant revenue line of late, investors have left Fluidigm (FLDM) for dead. The stock is down approximately 65% during the past 12 months as investors have lost confidence in the company's strategy, which has focused on providing the highest quality diagnostic equipment and consumables to academic laboratories. Unfortunately, this business has not